AR124712A1 - Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos - Google Patents
Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismosInfo
- Publication number
- AR124712A1 AR124712A1 ARP220100165A ARP220100165A AR124712A1 AR 124712 A1 AR124712 A1 AR 124712A1 AR P220100165 A ARP220100165 A AR P220100165A AR P220100165 A ARP220100165 A AR P220100165A AR 124712 A1 AR124712 A1 AR 124712A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- species
- antibody
- heavy chain
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Abstract
La invención proporciona composiciones de anticuerpos anti-PD-1 o fragmentos de unión a antígeno de los mismos con menos de, o igual a, aproximadamente un 3,0% de oxidación de Met105 en la región de cadena pesada de CDRH3, y métodos para obtener las composiciones purificadas. La invención también proporciona composiciones que comprenden especies principales de anticuerpos anti-PD-1 y especies ácidas de los mismos, en donde la cantidad de especies ácidas es de aproximadamente 1,0 - 12,0%. Reivindicación 1: Una composición que comprende un anticuerpo anti-PD-1 humano o un fragmento de unión al antígeno del mismo, en donde el anticuerpo anti-PD-1 humano o el fragmento de unión a antígeno del mismo comprende una región variable de cadena ligera que comprende tres CDR de cadena ligera que comprenden CDRL1 de SEQ ID Nº 1, CDRL2 de SEQ ID Nº 2 y CDRL3 de SEQ ID Nº 3 y una región variable de cadena pesada que comprende tres CDR de cadena pesada de CDRH1 de SEQ ID Nº 6, CDRH2 de SEQ ID Nº 7 y CDRH3 de SEQ ID Nº 8, en donde dicho anticuerpo o fragmento de unión a antígeno del mismo, tiene menos de, o igual a, aproximadamente un 3,0% de oxidación de Metionina 105. Reivindicación 12: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano producido a partir de una célula de ovario chino que comprende un polinucleótido que codifica una cadena ligera y un polinucleótido que codifica una cadena pesada, o un polinucleótido que codifica una cadena ligera y una cadena pesada, en donde la cadena pesada consiste en la secuencia de aminoácidos de SEQ ID Nº 10, 13 ó 15, y la cadena ligera consiste en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas de las especies principales del anticuerpo anti-PD-1 humano, en donde la cantidad de especies ácidas es de 1,0 - 12,0%. Reivindicación 13: Una composición que comprende una especie principal de anticuerpo anti-PD-1 humano que comprende un anticuerpo que consiste en dos cadenas pesadas y dos cadenas ligeras, consistiendo cada cadena pesada en la secuencia de aminoácidos de SEQ ID Nº 11, y consistiendo cada cadena ligera en la secuencia de aminoácidos de SEQ ID Nº 5, y especies ácidas y básicas de la especie principal del anticuerpo anti-PD-1 humano, en donde la cantidad de especies principales es de 65 - 85%.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163143461P | 2021-01-29 | 2021-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124712A1 true AR124712A1 (es) | 2023-04-26 |
Family
ID=80786902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100165A AR124712A1 (es) | 2021-01-29 | 2022-01-27 | Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220251205A1 (es) |
EP (1) | EP4284834A1 (es) |
JP (1) | JP2024505524A (es) |
CN (1) | CN117043194A (es) |
AR (1) | AR124712A1 (es) |
AU (1) | AU2022212007A1 (es) |
CA (1) | CA3206669A1 (es) |
TW (1) | TW202237657A (es) |
WO (1) | WO2022165001A1 (es) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
WO2008052101A2 (en) | 2006-10-25 | 2008-05-02 | President And Fellows Of Harvard College | Multiplex automated genome engineering |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
WO2012018538A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Bioassays for determining pd-1 modulation |
PL2794651T3 (pl) | 2011-12-22 | 2022-12-27 | F.Hoffmann-La Roche Ag | Kombinacje elementów wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US9790488B2 (en) | 2013-08-02 | 2017-10-17 | Agency For Science, Technology And Research | Mutated internal ribosomal entry site (IRES) for controlled gene expression |
JP2016526920A (ja) | 2013-08-05 | 2016-09-08 | トカジェン インコーポレーテッド | 最適化a−バルジを有する組換えベクター |
WO2015040402A1 (en) | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
EP3670660A1 (en) | 2014-04-09 | 2020-06-24 | Dna Twopointo Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
WO2016003368A1 (en) | 2014-07-01 | 2016-01-07 | Agency For Science, Technology And Research | Optimized vectors for the production of recombinant proteins |
JP2017534301A (ja) | 2014-11-10 | 2017-11-24 | マードック チルドレンズ リサーチ インスティチュート | 構成的に発現された遺伝子を含む遺伝子座における標的を狙った組み込みのためのベクター及び方法 |
US20170204446A1 (en) * | 2016-01-15 | 2017-07-20 | Artemis BioSystems Inc. | System for rapid continuous manufacturing of monoclonal antibodies |
US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
EP3724229A1 (en) * | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
WO2020068631A1 (en) | 2018-09-24 | 2020-04-02 | Merck Sharp & Dohme Corp. | Expression vectors for eukaryotic expression systems |
SG11202107441RA (en) | 2019-02-15 | 2021-08-30 | Just Evotec Biologics Inc | Automated biomanufacturing systems, facilities, and processes |
TW202045711A (zh) * | 2019-06-13 | 2020-12-16 | 美商安進公司 | 生物製品製造中基於生物量之自動灌注控制 |
-
2022
- 2022-01-27 AR ARP220100165A patent/AR124712A1/es unknown
- 2022-01-27 JP JP2023545829A patent/JP2024505524A/ja active Pending
- 2022-01-27 CN CN202280022248.0A patent/CN117043194A/zh active Pending
- 2022-01-27 WO PCT/US2022/014055 patent/WO2022165001A1/en active Application Filing
- 2022-01-27 US US17/586,109 patent/US20220251205A1/en active Pending
- 2022-01-27 TW TW111103668A patent/TW202237657A/zh unknown
- 2022-01-27 CA CA3206669A patent/CA3206669A1/en active Pending
- 2022-01-27 EP EP22704657.0A patent/EP4284834A1/en active Pending
- 2022-01-27 AU AU2022212007A patent/AU2022212007A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022165001A1 (en) | 2022-08-04 |
AU2022212007A1 (en) | 2023-09-07 |
JP2024505524A (ja) | 2024-02-06 |
TW202237657A (zh) | 2022-10-01 |
EP4284834A1 (en) | 2023-12-06 |
US20220251205A1 (en) | 2022-08-11 |
CA3206669A1 (en) | 2022-08-04 |
CN117043194A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
HRP20170444T1 (hr) | Projektirana anti-il-23 antitijela | |
PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
NZ623347A (en) | Novel anti-dr5 antibody | |
AR082194A1 (es) | Anticuerpos anti-ron | |
PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso |